Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with Chemotherapy and Relayed Radiotherapy in ES-SCLC
NCT06838208Phase 2Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Feb 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in small cell lung cancer (SCLC), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Progression Free Survival at 23 months. Started Feb 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06838208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06838208.